S. Hayman

Stem Cell Mobilization Following Initial Therapy with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2008 .

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

R. Fonseca, A. Dispenzieri, Shaji K. Kumar, 2007, Leukemia.

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience

D. Dingli, R. Kyle, S. Rajkumar, 2021, Blood cancer journal.

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

S. Mandrekar, A. Dispenzieri, Shaji K. Kumar, 2013, Leukemia.

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

D. Dingli, A. Dispenzieri, R. Kyle, 2016, Leukemia.

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

D. Dingli, R. Kyle, M. Gertz, 2021, Leukemia.

Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy

D. Dingli, A. Dispenzieri, M. Gertz, 2012, Leukemia.

Efficacy of pomalidomide plus low-dose dexamethasone in multiple myeloma patients despite previous use of lenalidomide.

R. Fonseca, A. Dispenzieri, V. Roy, 2011, Journal of Clinical Oncology.

Impact of dexamethasone responsiveness on long-term outcome in patients with newly diagnosed myeloma.

A. Dispenzieri, S. Rajkumar, S Kumar, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.